Share price pullbacks for Cardiff Oncology are typically triggered by micro-cap market volatility, cautious sentiment regarding clinical-stage drug development timelines, or periodic capital-raising equity offerings common among pre-revenue biotechnology firms. Because clinical progress updates and early-stage efficacy data readouts dictate valuation trajectories, any perceived delays or capital dilution concerns can prompt immediate downward adjustments from risk-averse institutional and retail market participants.